Infectious Diseases Society of America 2023 guidance on the treatment of antimicrobial resistant gram-negative infections
Abstract Background The Infectious Diseases Society of America is committed to providing
up-to-date guidance on the treatment of antimicrobial-resistant infections. This guidance …
up-to-date guidance on the treatment of antimicrobial-resistant infections. This guidance …
Infectious Diseases Society of America guidance on the treatment of AmpC β-lactamase–producing Enterobacterales, carbapenem-resistant Acinetobacter baumannii …
Abstract The Infectious Diseases Society of America (IDSA) is committed to providing up-to-
date guidance on the treatment of antimicrobial-resistant infections. A previous guidance …
date guidance on the treatment of antimicrobial-resistant infections. A previous guidance …
Infectious Diseases Society of America 2022 guidance on the treatment of extended-spectrum β-lactamase producing Enterobacterales (ESBL-E), carbapenem …
Abstract Background The Infectious Diseases Society of America (IDSA) is committed to
providing up-to-date guidance on the treatment of antimicrobial-resistant infections. The …
providing up-to-date guidance on the treatment of antimicrobial-resistant infections. The …
Ventilator-associated pneumonia in adults: a narrative review
Ventilator-associated pneumonia (VAP) is one of the most frequent ICU-acquired infections.
Reported incidences vary widely from 5 to 40% depending on the setting and diagnostic …
Reported incidences vary widely from 5 to 40% depending on the setting and diagnostic …
International consensus guidelines for the optimal use of the polymyxins: endorsed by the American college of clinical pharmacy (ACCP), European society of clinical …
The polymyxin antibiotics colistin (polymyxin E) and polymyxin B became available in the
1950s and thus did not undergo contemporary drug development procedures. Their clinical …
1950s and thus did not undergo contemporary drug development procedures. Their clinical …
The “old” and the “new” antibiotics for MDR gram-negative pathogens: for whom, when, and how
The recent expansion of multidrug resistant and pan-drug-resistant pathogens poses
significant challenges in the treatment of healthcare associated infections. An important …
significant challenges in the treatment of healthcare associated infections. An important …
[HTML][HTML] European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram …
Scope These ESCMID guidelines address the targeted antibiotic treatment of third-
generation cephalosporin-resistant Enterobacterales (3GCephRE) and carbapenem …
generation cephalosporin-resistant Enterobacterales (3GCephRE) and carbapenem …
Inhaled liposomal antimicrobial delivery in lung infections
The management of difficult-to-treat acute and chronic respiratory infections (infections in
cystic fibrosis, non-cystic fibrosis bronchiectasis, immunocompromised and mechanically …
cystic fibrosis, non-cystic fibrosis bronchiectasis, immunocompromised and mechanically …
[HTML][HTML] Management of KPC-producing Klebsiella pneumoniae infections
Background Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae (KPC-
KP) has become one of the most important contemporary pathogens, especially in endemic …
KP) has become one of the most important contemporary pathogens, especially in endemic …
Efficacy and safety of different polymyxin-containing regimens for the treatment of pneumonia caused by multidrug-resistant gram-negative bacteria: a systematic …
Y Zhou, G Wang, Y Zhao, W Chen, X Chen, Y Qiu… - Critical Care, 2024 - Springer
Background The optimal administration of polymyxins for treating multidrug-resistant gram-
negative bacterial (MDR-GNB) pneumonia remains unclear. This study aimed to …
negative bacterial (MDR-GNB) pneumonia remains unclear. This study aimed to …